GSK chair, directors buy shares on-market

Multiple GSK plc board members reported on-market purchases of Ordinary Shares and ADSs on September 18, 2026.

Rhea-AI Filing Summary

GSK plc (GSK) reports that several persons discharging managerial responsibilities, including Non-Executive Chair Sir Jonathan Symonds and multiple Independent Non-Executive Directors, purchased GSK securities on September 18, 2026 on the London Stock Exchange and New York Stock Exchange.

Transactions included purchases of Ordinary Shares in London and American Depositary Shares in New York at disclosed per-share prices in single, on-market trades for each individual.

Key Figures

Ordinary Shares purchased by Sir Jonathan Symonds: 1,500 shares at £18.8110 Ordinary Shares purchased by Roy Jackobs: 936 shares at £18.8100 ADSs purchased by Elizabeth McKee Anderson: 626 ADS at $49.8534 +5 more

8 metrics

Ordinary Shares purchased by Sir Jonathan Symonds 1,500 shares at £18.8110 On-market purchase on London Stock Exchange on September 18, 2026

Ordinary Shares purchased by Roy Jackobs 936 shares at £18.8100 On-market purchase on London Stock Exchange on September 18, 2026

ADSs purchased by Elizabeth McKee Anderson 626 ADS at $49.8534 On-market purchase on New York Stock Exchange on September 18, 2026

ADSs purchased by Charles Bancroft 1,734 ADS at $49.8534 On-market purchase on New York Stock Exchange on September 18, 2026

ADSs purchased by Dr Anne Beal 637 ADS at $49.8534 On-market purchase on New York Stock Exchange on September 18, 2026

ADSs purchased by Dr Hal Dietz 768 ADS at $49.8534 On-market purchase on New York Stock Exchange on September 18, 2026

ADSs purchased by Dr Jeannie Lee 653 ADS at $49.8534 On-market purchase on New York Stock Exchange on September 18, 2026

ADSs purchased by Dr Vishal Sikka 994 ADS at $49.8534 On-market purchase on New York Stock Exchange on September 18, 2026

Key Terms

American Depositary Shares, Ordinary Shares, PDMR, LEI, +2 more

6 terms

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares (‘ADS’)"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Ordinary Shares financial

"Description of the financial instrument | Ordinary shares of 31 ¼ pence each"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

PDMR regulatory

"Details of PDMR/person closely associated with them (‘PCA’)"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

LEI financial

"Name | GSK plc b) | LEI | 5493000HZTVUYLO1D793"

A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.

London Stock Exchange financial

"Place of the transaction | London Stock Exchange (XLON)"

A major regulated marketplace in London where stocks, bonds and other securities are bought and sold, the London Stock Exchange acts like a large, organized auction house that matches buyers and sellers and records current prices. It matters to investors because it provides liquidity and reliable price information, a platform for companies to raise capital, and rules that help protect market integrity — all of which affect portfolio value and trading opportunities.

New York Stock Exchange financial

"Place of the transaction | New York Stock Exchange (XNYS)"

The New York Stock Exchange is a marketplace where people buy and sell shares of publicly traded companies. It functions like a busy trading hub, helping investors transfer ownership of company parts and providing a way to gauge how well businesses are doing. Its role is vital because it offers liquidity and transparency, making it easier for investors to buy and sell investments confidently.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchases did GSK (GSK) disclose in this Form 6-K?

GSK disclosed that several board members made on-market purchases of its securities on September 18, 2026, including Ordinary Shares on the London Stock Exchange and American Depositary Shares (ADS) on the New York Stock Exchange, each reported as a single transaction per person.

Which GSK (GSK) directors bought Ordinary Shares and how many?

Sir Jonathan Symonds, Non-Executive Chair, purchased 1,500 Ordinary Shares at £18.8110 each, and Independent Non-Executive Director Roy Jackobs purchased 936 Ordinary Shares at £18.8100 each. Both trades occurred on September 18, 2026 on the London Stock Exchange.

Which GSK (GSK) directors bought ADSs and at what price?

Elizabeth McKee Anderson, Charles Bancroft, Dr Anne Beal, Dr Hal Dietz, Dr Jeannie Lee, and Dr Vishal Sikka each purchased GSK ADSs on September 18, 2026 at $49.8534 per ADS in single transactions on the New York Stock Exchange.

How many ADSs did each GSK (GSK) director purchase on the NYSE?

Reported ADS purchases were: Elizabeth McKee Anderson 626 ADS, Charles Bancroft 1,734 ADS, Dr Anne Beal 637 ADS, Dr Hal Dietz 768 ADS, Dr Jeannie Lee 653 ADS, and Dr Vishal Sikka 994 ADS, all on September 18, 2026.

On which exchanges were the GSK (GSK) insider transactions executed?

Ordinary Share purchases by Sir Jonathan Symonds and Roy Jackobs were executed on the London Stock Exchange (XLON), while ADS purchases by six Independent Non-Executive Directors were executed on the New York Stock Exchange (XNYS) on September 18, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 10:53 AM Accepted by SEC EDGAR 09/22/2026 - 10:52 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Sir Jonathan Symonds
b)	Position/status	Non-Executive Chair
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Purchase of 1,500 Ordinary Shares
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8110	1,500
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-09-18
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Elizabeth (Liz) McKee Anderson
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Purchase of 626 ADS
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.8534	626
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-09-18
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Charles Bancroft
b)	Position/status	Senior Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Purchase of 1,734 ADS
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.8534	1,734
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-09-18
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Dr Anne Beal
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Purchase of 637 ADS
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.8534	637
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-09-18
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Dr Hal Dietz
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Purchase of 768 ADS
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.8534	768
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-09-18
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Dr Jeannie Lee
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Purchase of 653 ADS
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.8534	653
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-09-18
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Dr Vishal Sikka
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Purchase of 994 ADS
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.8534	994
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-09-18
f)	Place of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Roy Jackobs
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Purchase of 936 Ordinary Shares
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8100	936
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-09-18
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: September 22, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc